PCSK9 - A New and Potent Approach to Lowering Cholesterol

PCSK9 - A New and Potent Approach to Lowering Cholesterol

Bibliographic Details
Main Author:	Thomas F. Whayne Jr.
Format:	Article
Language:	English
Published:	Oman Medical Specialty Board 2013-05-01
Series:	Oman Medical Journal
Subjects:	PCSK9 Cholesterol.
Online Access:	http://www.omjournal.org/fultext_PDF.aspx?DetailsID=370&type=fultext

Similar Items

Asociation of PCSK9 with Low Density Lipoproteins (LDL) in the Regulation of LDL-Cholesterol Levels
by: Sarkar, Samantha Khadija
Published: (2015)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
by: Ioanna Gouni-Berthold, et al.
Published: (2014-12-01)

<i>Acanthaster planci</i> Inhibits PCSK9 and Lowers Cholesterol Levels in Rats
by: Nurjannatul Naim Kamaruddin, et al.
Published: (2021-08-01)

Rôle de PCSK9 et conséquences des chirurgies bariatriques sur le métabolisme intestinal du cholestérol
by: Moreau, François
Published: (2017)

PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma
by: Silvano Fasolato, et al.
Published: (2020-09-01)

Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice
by: Jean-Mathieu Berger, et al.
Published: (2017-08-01)

Successful treatment of cholesterol crystal embolism with anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody: a case report
by: Junki Morino, et al.
Published: (2020-01-01)

More on Cholesterol Trafficking in the Body!
by: Khawla Al-Musalhi, et al.
Published: (2013-03-01)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
by: Sanjiv Gupta
Published: (2015-09-01)

Naturally Occurring PCSK9 Inhibitors
by: Maria Pia Adorni, et al.
Published: (2020-05-01)

Correlation of PCSK9 and Serum sdLDL Levels and Other Demographic and Laboratory Indicators in Healthy Individuals
by: Reza Hosseini-Fard, et al.
Published: (2018-05-01)

PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
by: A O Averkova
Published: (2017-09-01)

The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process – is there a link?
by: Malwina Grobelna, et al.
Published: (2019-10-01)

New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects
by: Qidi Ying, et al.
Published: (2021-02-01)

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans
by: Jeffrey D. Browning, et al.
Published: (2010-11-01)

PCSK9 and cancer: Rethinking the link
by: Khadijeh Mahboobnia, et al.
Published: (2021-08-01)

Role of PCSK9 in Homocysteine-Accelerated Lipid Accumulation in Macrophages and Atherosclerosis in ApoE−/− Mice
by: Ping Jin, et al.
Published: (2021-10-01)

Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2019-12-01)

PCSK9: A New Target for Lipid-Lowering Therapy
by: Nutjaree Jeenduang
Published: (2014-04-01)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
by: Aureli Luquero, et al.
Published: (2021-03-01)

The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9
by: Brian T Emmer, et al.
Published: (2018-09-01)

Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice
by: Tsuyoshi Yamamoto, et al.
Published: (2012-01-01)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
by: Piotr Pęczek, et al.
Published: (2021-05-01)

Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2021-07-01)

Cholesterol-lowering pattern affects the progression of atherosclerosis in apolipoprotein E deficient mice
by: Yusuke Masuda, et al.
Published: (2016-12-01)

Low-density lipoprotein cholesterol lowering treatment: the current approach
by: Irina Crismaru, et al.
Published: (2020-05-01)

An investigation into statins, PCSK9 inhibitors, and other current cholesterol treatments
by: Kiley, Mark E.
Published: (2018)

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
by: Saeideh Sobati, et al.
Published: (2020-08-01)

PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
by: Ioanna Andreadou, et al.
Published: (2020-11-01)

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
by: Julius L. Katzmann, et al.
Published: (2020-11-01)

The Functional Characterization of PCSK9's Binding Interactions with LDL and the LDL Receptor
by: Matyas, Angela
Published: (2020)

Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
by: Mba CM, et al.
Published: (2019-12-01)

Comparing expression and activity of PCSK9 in SPRET/EiJ and C57BL/6J mouse strains shows lack of correlation with plasma cholesterol
by: Francine Sirois, et al.
Published: (2017-03-01)

Inhibitory proproteinowej konwertazy subtylizyny/keksyny 9 nowym, przełomowym narzędziem terapeutycznym w leczeniu dyslipidemii = Proprotein convertase subtilisin/kexin type 9 inhibitors are a new, groundbreaking therapeutic tool in the treatment of dyslipidemia
by: Łukasz Wołowiec, et al.
Published: (2016-07-01)

PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions
by: Lοukianos S. Rallidis, et al.
Published: (2016-03-01)

Élucidation et identification des différents interacteurs impliqués dans le mécanisme de régulation du LDLR par la protéine PCSK9
by: Ly, Kévin
Published: (2016)

Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
by: Ye-Xuan Cao, et al.
Published: (2019-11-01)

Lipid-lowering treatment in the improvement of outcomes in patients with atherosclerotic cardiovascular disease and diabetes mellitus: the role of PCSK9 inhibitors
by: G. R. Galstyan, et al.
Published: (2018-12-01)

Effect of Physical Activity on Plasma PCSK9 in Subjects With High Risk for Type 2 Diabetes
by: Kari Antero Mäkelä, et al.
Published: (2019-04-01)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
by: A. A. Shikaleva, et al.
Published: (2021-01-01)

Cannot write session to /tmp/vufind_sessions/sess_kqegub0sh62dh5vj2p0m1cv42c